SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-012288 to KINETA, INC./DE (KA) (CIK 0001445283)

KINETA, INC./DE (KA) (CIK 0001445283)
Date: Nov. 9, 2023 · CIK: 0001445283 · Accession: 0000000000-23-012288

AI Filing Summary & Sentiment

File numbers found in text: 333-275309

Date
November 9, 2023
Author
Not clearly detected
Form
UPLOAD
Company
KINETA, INC./DE (KA) (CIK 0001445283)

Letter

United States securities and exchange commission logo November 9, 2023 Shawn Iadonato, Ph.D. Chief Executive Officer KINETA, INC./DE 219 Terry Ave. N., Suite 300 Seattle, WA 98109 Re:KINETA, INC./DE Registration Statement on Form S-3 Filed November 3, 2023 File No. 333-275309 Dear Shawn Iadonato: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kelly Mink

Show Raw Text
United States securities and exchange commission logo
November 9, 2023
Shawn Iadonato, Ph.D.
Chief Executive Officer
KINETA, INC./DE
219 Terry Ave. N., Suite 300
Seattle, WA 98109
Re:KINETA, INC./DE
Registration Statement on Form S-3
Filed November 3, 2023
File No. 333-275309
Dear Shawn Iadonato:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Kelly Mink